Effect of Rebound Pain on Chronic Postsurgical Pain After Total Knee Arthroplasty

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorKonya City Hospital

About this trial

This prospective observational study aims to evaluate whether rebound pain after peripheral nerve block is associated with the development of chronic postsurgical pain following elective total knee arthroplasty. Adult patients undergoing unilateral total knee arthroplasty under spinal anesthesia and receiving a peripheral nerve block as part of routine multimodal analgesia will be included. No additional intervention, drug administration, or biological sampling will be performed beyond standard clinical care.

Rebound pain will be assessed during the early postoperative period using pain diaries, numeric rating scale pain scores, and analgesic consumption records. Chronic postsurgical pain and related outcomes will be evaluated at postoperative 3 and 6 months using validated instruments assessing pain severity, neuropathic pain features, psychological status, functional outcomes, and health-related quality of life. The primary outcome is the presence of chronic postsurgical pain at 3 months after surgery. Secondary outcomes include chronic pain at 6 months, pain intensity, neuropathic pain characteristics, opioid consumption, rescue analgesic requirements, sleep disturbance, and quality-of-life measures. The study also aims to explore demographic and clinical factors associated with rebound pain and chronic postsurgical pain.

Eligibility criteria

Qualifiers

Age 18 years or older

ASA physical status I to III

Scheduled for unilateral elective total knee arthroplasty

Planned to undergo spinal anesthesia

Disqualifiers

Chronic opioid use (60 mg oral morphine equivalent per day or more, or use for 3 months or longer)

Significant neuropathy or radiculopathy

Bilateral or two-stage total knee arthroplasty during the same hospitalization

Contralateral total knee arthroplasty within the previous 6 months

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

220 Participants
are grouped into 2 trial groups

Locations

This trial has no locations

Sponsors and collaborators